Drug Trial Radar · NCT00564941
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload
Last checked: Nov 20, 2026Latest source record: Feb 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
309
Planned (sponsor's estimate)
Start
Dec 2007
Primary completion
Jul 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 29, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of deferasirox in transfusion dependent Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overload
Conditions
- Myelodysplastic Syndromes
- Beta-Thalassemia
Interventions
deferasiroxDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- This study will evaluate the safety and efficacy of deferasirox in transfusion dependent Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overloadTime frame: monthly during the therapy and at the end of the treatment (aftr 9 months therapy)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Debrecen, Hungary
Novartis Investigative Site
Pécs, Hungary
Novartis Investigative Site
Szeged, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.